IBM’s Mainframe Surge Fails to Offset Investor Jitters

IBM shares tumbled in extended trading Wednesday, shedding nearly 7% of their value despite the company posting first-quarter results that handily beat Wall Street forecasts. The sell-off erased over $17 billion in market capitalization as investors focused on a cautious outlook and a weak consulting performance rather than a blockbuster 51% surge in new mainframe sales.

For the quarter, the technology giant reported revenue of $15.92 billion, surpassing estimates by approximately $300 million. Adjusted earnings per share came in at $1.91, also topping the consensus forecast of $1.81. A year earlier, IBM had posted EPS of $1.60.

The standout performer was the infrastructure unit, where revenue climbed 15% year-over-year. This growth was powered by the successful launch of the new Z-series mainframe, with sales skyrocketing 51%. The company’s software segment, anchored by its Red Hat subsidiary, continued to be a steady driver as well.

However, the report revealed clear soft spots. Revenue from IBM’s consulting business missed expectations, landing at $5.27 billion. CFO Jim Kavanaugh pointed to delayed government contracts and hardware supply chain disruptions as key factors holding back the segment.

Should investors sell immediately? Or is it worth buying IBM?

Management’s forward guidance did little to reassure the market. Despite the strong start to the year and the recent, accelerated closing of its $11 billion acquisition of Confluent in mid-March, IBM merely reaffirmed its existing full-year targets. The company continues to project revenue growth of more than 5% and maintained its free cash flow forecast. CEO Arvind Krishna cited the Iran conflict and broader geopolitical uncertainties as reasons for this conservative stance.

This caution has been mirrored by analysts in recent days. Several investment banks trimmed their price targets ahead of the earnings release, citing sector-wide software weakness rather than IBM-specific issues. Jefferies lowered its target to $320 while maintaining a Buy rating, and RBC Capital Markets reduced its target to $330 with an Outperform rating. Morgan Stanley holds a more pessimistic view with a $215 target, while Wedbush remains bullish with a $340 target and an Outperform rating.

The stock’s performance has been under pressure all year. In regular trading Wednesday, shares closed at €217.90, leaving them down 12.37% since January. The company is expected to announce its 27th consecutive annual dividend increase in April, with the quarterly payout anticipated to rise slightly to $1.6875 per share from the current $1.69.

For now, the market’s verdict is clear. Investors are looking past the powerful mainframe cycle and are demanding a return to growth in the consulting division and more confident guidance, leaving IBM’s stock searching for a solid footing.